title: Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential.
abstract: The authors investigated the roles of PI3-kinase and PLC-gamma in stimulation by Steel Factor (SLF) through c-Kit. c-Kit mutants YF719, YF728, and a YF719/YF728 double mutant were expressed in 32D myelomonocytic cells. KitYF719 fails to recruit PI3-kinase after stimulation with SLF, whereas KitYF728 fails to stimulate PLC-gamma phosphorylation or mobilize Ca(++). Both single mutants responded mitogenically to soluble SLF (sSLF) in a manner indistinguishable from wild type (WT), although sSLF failed to stimulate or promote the survival of cells expressing the double mutant. In contrast, although cells expressing WT or YF719 were mitogenically stimulated by membrane-bound SLF (mSLF), stimulation of cells expressing KitYF728 was impaired. Similarly, cells expressing WT or YF719 receptors were stimulated by plate-bound anti-Kit antibodies, whereas cells expressing the YF728 receptor were not stimulated. Neomycin sulfate, a PLC antagonist, inhibited cells expressing YF719 receptors stimulated by sSLF. Neomycin also inhibited cells expressing the WT receptor that were stimulated by mSLF or immobilized anti-Kit antibodies but did not inhibit stimulation of cells expressing WT or YF719 receptors by sSLF. 32D cells expressing KitWT, KitYF719, or KitYF728 were injected into mice and the presence of cells was evaluated by colony assays 6 to 7 weeks later. Although both KitWT and KitYF719 expressing cells could be recovered from the spleen and bone marrow, recovery of KitYF728 cells from these organs was severely reduced. These results indicate that Kit tyrosine 728 is of particular importance for mitogenic stimulation by mSLF or immobilized ligand and is required for full maintenance of cells in vivo, likely through activation of PLC-gamma. (Blood. 2000;96:3734-3742)
authors.affiliation: The Arthritis and Immune Disorder Research Centre, The Toronto Hospital, University of Toronto, Toronto, Ontario, Canada.
authors.forename: J L
authors.initials: JL
authors.lastname: Gommerman
authors.forename: D
authors.initials: D
authors.lastname: Sittaro
authors.forename: N Z
authors.initials: NZ
authors.lastname: Klebasz
authors.forename: D A
authors.initials: DA
authors.lastname: Williams
authors.forename: S A
authors.initials: SA
authors.lastname: Berger
mesh_terms: D000818:Animals; D000906:Antibodies / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects; D004789:Enzyme Activation / Q000502:physiology; D006801:Humans; D007527:Isoenzymes / Q000737:chemistry / Q000378:metabolism / Q000502:physiology; D007938:Leukemia / Q000201:enzymology / Q000209:etiology*; D008565:Membrane Proteins / Q000494:pharmacology*; D051379:Mice; D008934:Mitogens / Q000494:pharmacology; D016297:Mutagenesis, Site-Directed; D009355:Neomycin / Q000494:pharmacology; D019869:Phosphatidylinositol 3-Kinases / Q000737:chemistry / Q000378:metabolism / Q000502:physiology; D051966:Phospholipase C gamma; D010766:Phosphorylation; D021122:Protein Subunits; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects* / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D012995:Solubility; D019089:Stem Cell Factor / Q000494:pharmacology*; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects; D010738:Type C Phospholipases / Q000737:chemistry / Q000378:metabolism / Q000502:physiology; D018909:src Homology Domains / Q000502:physiology
chemical_list: D000906:Antibodies; D007527:Isoenzymes; D008565:Membrane Proteins; D008934:Mitogens; D021122:Protein Subunits; D019089:Stem Cell Factor; D019869:Phosphatidylinositol 3-Kinases; D019009:Proto-Oncogene Proteins c-kit; D010738:Type C Phospholipases; D051966:Phospholipase C gamma; D009355:Neomycin